Regeneron Pharmaceuticals Inc (NAS:REGN)
$ 714.47 -0.66 (-0.09%) Market Cap: 78.51 Bil Enterprise Value: 71.42 Bil PE Ratio: 17.68 PB Ratio: 2.68 GF Score: 88/100

Regeneron Pharmaceuticals Inc at Morgan Stanley Global Healthcare Conference Transcript

Sep 12, 2022 / 03:05PM GMT
Release Date Price: $710.74 (-1.87%)
Matthew Kelsey Harrison
Morgan Stanley, Research Division - Executive Director

Good morning, everybody. Thanks for joining us for the next session. I'm Matthew Harrison, one of the biotech analysts here at Morgan Stanley. Very pleased to have Regeneron with us here for the next session. Just quickly before we get started, I just need to read a disclosure statement. Please note that all important disclosures, including personal holdings disclosures, are available on the Morgan Stanley public website at morganstanley.com/researchdisclosures.

So with that, really pleased, we have Len Schleifer, the CEO; Marion McCourt, who runs Commercial; and Ryan Crowe from IR. So really pleased to have you all here. Maybe a good place to start is obviously what came last week. It is last week, right? With the high-dose EYLEA data, so -- I mean, just -- how does that change your view on the long-term opportunity for EYLEA and how you think about basically investment behind that molecule now?

Ryan Crowe
Regeneron Pharmaceuticals, Inc. - VP of IR

Maybe before Len gets

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot